Pharvaris (PHVS) Expected to Announce Earnings on Tuesday

Pharvaris (NASDAQ:PHVS) is expected to post its results before the market opens on Tuesday, May 12th. Analysts expect Pharvaris to post earnings of ($0.8267) per share for the quarter.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Stock Performance

Shares of PHVS traded up $0.22 during mid-day trading on Tuesday, hitting $30.24. 96,907 shares of the company were exchanged, compared to its average volume of 197,820. Pharvaris has a 1-year low of $14.59 and a 1-year high of $31.14. The company has a 50 day moving average of $27.62 and a 200-day moving average of $26.09. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -8.97 and a beta of -2.34.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Royal Bank Of Canada reduced their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wedbush upped their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Finally, Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.73.

Insider Activity

In other news, insider Anne Lesage sold 19,200 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total value of $580,992.00. Following the completion of the sale, the insider owned 133,969 shares of the company’s stock, valued at $4,053,901.94. This represents a 12.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Peng Lu sold 15,000 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the completion of the sale, the insider directly owned 66,083 shares of the company’s stock, valued at approximately $1,998,349.92. This trade represents a 18.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 150,659 shares of company stock valued at $4,489,587 in the last 90 days.

Institutional Trading of Pharvaris

Hedge funds have recently made changes to their positions in the company. Barclays PLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at approximately $77,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of Pharvaris by 39.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after purchasing an additional 1,769 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Pharvaris by 50.1% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 8,239 shares of the company’s stock worth $229,000 after purchasing an additional 2,750 shares during the period. Finally, Alliancebernstein L.P. purchased a new position in shares of Pharvaris during the 3rd quarter worth approximately $224,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.